Our group has also reported p16 abrogation rates upwards of 90% in primary T-cell lymphoblastic leukemia, demonstrating the importance of INK4A inactivation in the progression of blood cancers as well as solid-tumors [5]. The gene discussed is CDKN2A; the disease is hematopoietic and lymphoid system neoplasm.